TELA Bio Secures FDA 510(k) Clearance for Liora Monofilament Scaffold
TELA has more than doubled off its 52-week low of $0.501.
Summary
TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. The product is the first developed in-house at the company's ISO 8 cleanroom and expands its soft tissue reconstruction portfolio.
Key Events · Product Development and Regulatory · TELA
-
FDA 510(k) Clearance for Liora
TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement.
-
First In-House Developed Product
Liora is the first implant fully developed in the company's ISO 8 certified cleanroom in Malvern, PA, and the first fully resorbable synthetic product in its portfolio.
-
Commercial Expansion Opportunity
The clearance expands TELA Bio's soft tissue reconstruction portfolio and gives surgeons and patients additional options, with more details expected on the Q3 earnings call in early November.
-
Strategic Context
The clearance comes as TELA Bio faces a Nasdaq delisting notice, a going-concern warning, and a reverse stock split vote scheduled for October 8, 2026.
Analysis · TELA · Industrial Applications And Services
TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This is the first product fully developed in the company's ISO 8 certified cleanroom and the first fully resorbable synthetic product in its portfolio. The clearance expands TELA Bio's product line and gives it a new commercial opportunity at a critical time — the company is facing a Nasdaq delisting notice, a going-concern warning, and a reverse stock split vote on October 8. A new FDA-cleared product could help stabilize revenue and investor sentiment, though commercial launch timing and market acceptance remain uncertain.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELA was trading at $1.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $51.5M. The 52-week trading range was $0.50 to $1.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.